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Targeted exome sequencing resolves allelic and the
genetic heterogeneity in the genetic diagnosis of
nephronophthisis-related ciliopathy
Hee Gyung Kang1,12, Hyun Kyung Lee1,12, Yo Han Ahn1, Je-Gun Joung2, Jaeyong Nam2, Nayoung KD Kim2,
Jung Min Ko1, Min Hyun Cho3, Jae Il Shin4, Joon Kim5, Hye Won Park6, Young Seo Park7, Il-Soo Ha1,
Woo Yeong Chung8, Dae-Yeol Lee9, Su Young Kim10, Woong Yang Park2,11 and Hae Il Cheong1
Nephronophthisis-related ciliopathy (NPHP-RC) is a common genetic cause of end-stage renal failure during childhood and
adolescence and exhibits an autosomal recessive pattern of inheritance. Genetic diagnosis is quite limited owing to genetic
heterogeneity in NPHP-RC. We designed a novel approach involving the step-wise screening of Sanger sequencing and targeted
exome sequencing for the genetic diagnosis of 55 patients with NPHP-RC. First, ﬁve NPHP-RC genes were analyzed by Sanger
sequencing in phenotypically classiﬁed patients. Known pathogenic mutations were identiﬁed in 12 patients (21.8%);
homozygous deletions of NPHP1 in 4 juvenile nephronophthisis patients, IQCB1/NPHP5 mutations in 3 Senior–Løken syndrome
patients, a CEP290/NPHP6 mutation in 1 Joubert syndrome patient, and TMEM67/MKS3 mutations in 4 Joubert syndrome
patients with liver involvement. In the remaining undiagnosed patients, we applied targeted exome sequencing of 34 ciliopathy-
related genes to detect known pathogenic mutations in 7 (16.3%) of 43 patients. Another 18 likely damaging heterozygous
variants were identiﬁed in 13 NPHP-RC genes in 18 patients. In this study, we report a variety of pathogenic and candidate
mutations identiﬁed in 55 patients with NPHP-RC in Korea using a step-wise application of two genetic tests. These results
support the clinical utility of targeted exome sequencing to resolve the issue of allelic and genetic heterogeneity in NPHP-RC.
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INTRODUCTION
Nephronophthisis (NPHP) should be included in the differ-
ential diagnosis of children or adolescents presenting with
chronic renal failure (CRF) of unknown etiology, because
NPHP is the most common (accounting for ~ 3%) monogenic
autosomal recessive cause of CRF in this age group.1–3 NPHP is
clinically characterized by anemia and growth retardation due
to impaired renal function as well as polyuria/nocturia and
polydipsia due to decreased renal concentrating ability.
Urinalysis often appears normal,4 and blood pressure is
typically not high. Commonly, ultrasonography reveals
normal-sized or relatively small kidneys that are distinctive
from autosomal recessive or autosomal dominant polycystic
kidney disease (ARPKD or ADPKD)5 and lack corticomedul-
lary differentiation. NPHP is often accompanied by defects in
other organs and tissues, for example, the retina, cerebellum
and liver, such as in Joubert syndrome, Senior–Løken
syndrome and Meckel–Gruber syndrome (MKS). A collective
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term, NPHP-related ciliopathy (NPHP-RC), is used to describe
this group of diseases, because most of the causative genes in
these disorders encode proteins that have a role in the
cilium.6–8
A genetic diagnosis is required for a deﬁnitive diagnosis of
NPHP-RC, because the clinical features of patients with
NPHP-RC are rather non-speciﬁc, and their symptoms overlap
signiﬁcantly.8 The most common genetic cause of NPHP is a
large deletion of NPHP1,9–11 which is noted in 420% of
patients with NPHP, whereas other genes contribute less than
2–3%.7 Sanger sequencing of commonly mutated NPHP genes
detects mutations in less than one-third of patients.8 In
addition, the number of NPHP-RC-related genes has been
rapidly increasing, with 20 genes having NPHP as part of
their gene name at the time of writing, especially after the
introduction of next-generation sequencing (NGS)
techniques.12–14 Therefore, the genetic diagnosis of NPHP-RC
based on an ‘educated guess at the best candidate gene’ is now
changing to adopting high-throughput genome analysis tech-
niques. Through NGS screening of known and candidate genes,
a genetic diagnosis can be obtained efﬁciently in more patients,
and novel causative genes can be identiﬁed. However, this
technology is still evolving, and it is relatively costly and
requires advanced bioinformatics support for handling large
quantities of data. Therefore, the combination of both tradi-
tional Sanger sequencing and NGS might be more practical in
obtaining a genetic diagnosis of NPHP-RC or other genetically
heterogeneous groups of disorders.
We report here the use of a stratiﬁed two-step procedure of
Sanger sequencing of selected genes followed by targeted exome
sequencing of 34 disease-related genes, which led to a genetic
diagnosis for 19 (34.5%) of our cohort of 55 Korean patients
with NPHP-RC clinical diagnoses.
MATERIALS AND METHODS
Study population
This study was approved by the independent review board of Seoul
National University Hospital (H-0812-002-264), and only those
patients who provided written informed consent were screened and
included in this study. Patients who were clinically diagnosed with
NPHP were included.15 Presentation with incidentally identiﬁed CRF
in the ﬁrst three decades of life without evidence of previous renal
damage was typical. Other causes of CRF were excluded by past
medical history and imaging of the urinary tract in the majority of the
cases. Patients with a clinical diagnosis of ADPKD were excluded. One
patient (J-86) was included owing to typical ﬁndings of Joubert
syndrome (cerebellar vermis aplasia, Leber congenital amaurosis and
mental retardation) without renal involvement. We performed fundus
examinations and abdominal sonography to evaluate the intra-
abdominal organs. Renal ultrasonographic ﬁndings of increased
echogenicity (normal or slightly decreased size for age) and cortico-
medullary differentiation loss were considered to be typical for NPHP-
RC.5 For those individuals with developmental delay and neurological
problems, we requested brain imaging. For some patients (n= 15),
renal pathology was also obtained, which exhibited typical ﬁndings of
chronic tubular interstitial disease. This study adheres to the Declara-
tion of Helsinki.
The patients were classiﬁed according to their age at the time of
end-stage renal disease as infantile when younger than 5 years old
(n= 11) and juvenile when older (n= 44). Combinations of NPHP
with cerebellar vermis hypoplasia or aplasia were designated as Joubert
syndrome (n= 8). Retinal involvement with retinitis pigmentosa (RP)
or Leber’s congenital amaurosis was designated as Senior–Løken
syndrome (n= 13), and those patients with multiple problems without
cerebellar hypo/aplasia were designated as MKS-like (n= 3).
Sanger sequencing
The most probable candidate genes were selected for Sanger sequen-
cing based on known mutation frequencies and speciﬁc clinical
phenotypes (Figure 1). Peripheral blood mononuclear cells were
collected from the patients, and genomic DNA was obtained using a
Figure 1 Strategy for Sanger sequencing. All of the patients were screened for complete deletions of NPHP1, which is the most common
mutation in NPHP. Among those without complete NPHP1 deletion, infant NPHP patients were tested for INVS/NPHP2 mutations. IQCB1/
NPHP5, CEP290/NPHP6, and TMEM67/MKS3/NPHP11 were tested according to the phenotypes of the patients. Crbll, cerebellar;
F, female; M, male; NPHP, nephronophthisis; RP, retinitis pigmentosa; SNHL, sensory neural hearing loss.
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QIA amp DNA Blood Mini Kit (Qiagen, Hilden, Germany). All of the
patients (n= 55) were screened for large deletions of NPHP1, which is
the most common mutation in NPHP, by amplifying each of the
exons using PCR; a failure of ampliﬁcation was considered to be a
total homozygous deletion of the NPHP1 gene.10,16 Among those
patients without large deletions of NPHP1, infantile NPHP patients
were tested for INVS/NPHP2 mutations (n= 11).17 The selection of
genes according to phenotype was as follows: IQCB1/NPHP5 for RP
(n= 19);18 CEP290/NPHP6 for Joubert syndrome (n= 8);19 and
TMEM67/MKS3 for hepatic ﬁbrosis (n= 7).20,21
Targeted exome sequencing
We designed customized targeted exome capture using a SeqCap EZ
kit (Roche NimbleGen, Madison, WI, USA) for 34 genes related to
NPHP-RC, Bardet–Biedl syndrome and ARPKD (Supplementary
Table S1). After capturing the target sequences, the DNA libraries
were ampliﬁed and sequenced using Illumina HiSeq2000 (Illumina,
San Diego, CA, USA).
Alignment, coverage calculation and variant detection
Reads were aligned to the UCSC hg19 reference genome using
BWA-0.6.1 with default settings22 for single-nucleotide variation
(SNV)/insertion and deletion (indel) detection, and duplicate reads
were removed. Variants were identiﬁed using Uniﬁed Genotyper in
GATK-1.3.23 A Perl script and Annovar were used to annotate variants
and search the known SNPs and indels from dbSNP v135 and the
1000 Genomes project data (drafted February 2012). Coverage and
depth were calculated using the GATK DepthOfCoverage analysis. The
signiﬁcance of variants was assessed in silico using MutationTaster,
PolyPhen-2, SIFT and FATHMM. Those variants predicted to be
disease causing or not tolerated by two or more programs were
considered to be pathogenic mutations.24–27 Conservation scores
(Phylo-P) for each mutated nucleotide were also considered.28
Prediction of alternative splicing by intronic variation was performed
using NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/), Ex-skip
(http://ex-skip.img.cas.cz/), and BDGP acceptor site prediction
(http://www.fruitﬂy.org/seq_tools/other.html).
Variant calls were obtained using the following ﬁlter parameter:
minimum base quality of 17 (the default value for the GATK Uniﬁed
Genotyper). A minimum variant count of 10 was applied for potential
truncating mutations (nonsense, frameshift and obligatory splice-site
mutations), and non-synonymous missense variants were ﬁltered by a
minimum count of 3. Synonymous variants and common dbSNP
(v135) variants with a population allele frequency 41% were
excluded.
All of the candidate mutations were validated by Sanger sequencing.
When available, we veriﬁed their co-segregation in the family (J-61
and J-50).
RESULTS
Clinical features of NPHP-RC patients
We recruited 55 unrelated Korean patients with a clinical
diagnosis of NPHP (M:F= 34:21) who were referred to our
laboratory for genetic diagnosis (Supplementary Table S1). The
mean age of the patients at end-stage renal disease was 9.0± 5.1
years old (median, 8.3 years; range, 0.6–17.9 years). Renal
histology from 15 patients exhibited typical ﬁndings of
tubulointerstitial nephropathy. Nineteen patients (34%) had
eye involvement of RP or Leber’s congenital amaurosis, eight
patients (14.5%) had a molar tooth sign in the brainstem on
brain imaging and seven patients (12.7%) exhibited hepatic
ﬁbrosis. Eight patients (14.5%) had siblings with similar
symptoms; however, none of their parents had CRF.
First step: Sanger sequencing for genetic diagnosis
As a ﬁrst step in the stratiﬁed approach to determine a genetic
diagnosis of NPHP, we selected and screened the patients by
Sanger sequencing for candidate genes (Figure 1). A homo-
zygous deletion of NPHP1 was detected in four patients
(7.3% (conﬁdence interval (CI, 95%) 0.4–14.2%), and 17%
of patients exhibited juvenile isolated NPHP without other
organ involvement (n= 23); Table 1, in bold). Three (15.8%)
of 19 NPHP patients with RP or Leber’s congenital amaurosis
(Senior- Løken syndrome, marked with ♣ in Figure 1)
carried a common pathogenic homozygous mutation
(c.1522_1523dupGA, p.Ala509Lysfs*3) in the IQCB1/NPHP5
genes.29 In screening NPHP patients with cerebellar vermis
hypotrophy/atrophy involvement (n= 8, marked with ♦ in
Figure 1), one familial case of Joubert syndrome had a
compound heterozygous mutation in CEP290/NPHP6, a
known pathogenic c.1666delA, p.Ile556Phefs*17,30 and an
SNV (c.6011-12T4A) that is predicted to cause alternative
splicing.31 Four of seven NPHP patients with hepatic ﬁbrosis
(marked with ♣ in Figure 1) carried compound heterozygous
mutations in TMEM67/MKS3/JBSTS6, a frameshift, truncating
mutation and an SNV.32–34 All four of these patients had
Joubert syndrome and congenital hepatic ﬁbrosis compatible
with COACH (cerebellar vermis hypoplasia/aplasia, oligophre-
nia, congenital ataxia, ocular coloboma and hepatic ﬁbrosis)
syndrome.35 In total, Sanger sequencing detected genetic
aberrations in 12 patients (21.8%) with a clinical diagnosis of
NPHP-RC.
Second step: Targeted exome sequencing in patients with
NPHP-RC
Targeted exome sequencing of 34 NPHP-RC-related genes was
applied in 43 patients in whom a genetic diagnosis was not
obtained by our ﬁrst step of Sanger sequencing. We obtained
an average 21.8Mb of mapped data per individual for ~ 166 kb
of targeting and ﬂanking regions (Supplementary Table S2).
The mean read depth was 131± 55 and 95.4% of the captured
target exons exhibited 410-fold coverage. Most likely
azpathogenic mutations of various types were identiﬁed in 7
of 43 cases (16%) in six genes, including NPHP1, NPHP3,
NPHP4, SDCCAG8/NPHP10, TTC21B/NPHP12 and PKHD1
(Figure 2). In three cases (K-8, J-84, K-9, Table 2), a
heterozygous known pathogenic mutation in BBS4 was identi-
ﬁed that could not explain the genetic pathogenesis but might
explain a mild phenotype resembling BBS, as previously
reported.36,37 Heterozygous potentially damaging mutations/
variations in at least one of the target NPHP-RC genes were
identiﬁed in additional 15 patients, including one truncating
mutation of NPHP3 in two patients with isolated juvenile
NPHP. In the remaining 18 patients, no signiﬁcant variations
of the target genes were identiﬁed. In total, we identiﬁed most
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likely pathogenic mutations in nine NPHP-RC-related genes in
19 (34.5%) of 55 Asian NPHP-RC patients using a two-step
genetic diagnosis (Figure 2), where the frequency of homo-
zygous deletion of NPHP1 is relatively low (7.3%, CI 0.4–14.2).
DISCUSSION
The genetic causes of several Mendelian diseases, such as
NPHP-RC, RP, and non-syndromic hearing loss, are hetero-
geneous. For these diseases, providing a precise diagnosis is
often difﬁcult until pathogenic mutations are identiﬁed. In the
present study, we obtained a genetic diagnosis in one-third of
patients with a clinical diagnosis of NPHP-RC with a two-step
genetic diagnosis using Sanger sequencing followed by high-
throughput mutation analysis using NGS after a custom
DNA-capture procedure. For two patients (K-7 and O-463),
mutation analysis led to correction of their diagnoses from
NPHP to ARPKD. Patients with ARPKD may have normal-
sized kidneys and therefore may be misdiagnosed with NPHP,
as shown here. In addition, additional heterozygous mutations
were identiﬁed in candidate genes from NGS (data not shown),
implying that further study of the respective genes or other
closely related genes would enhance the efﬁcacy of genetic
diagnosis of NPHP-RC. For the deﬁnitive genetic diagnosis of
NPHP-RC patients, extensive analysis of trio or family studies
of NPHP-RC will be followed to understand the penetrance of
genetic alterations and recurrence in additional patients.
Systemic functional studies on the variant proteins will also
be required to understand the effects of genetic alterations.
Traditionally, genetic diagnosis has been obtained by Sanger
sequencing of the best candidate genes based on disease
phenotype and frequency. The same approach was applied
for our NPHP-RC patients as our ﬁrst step, and 22% of the
patients were given genetic diagnosis with a fair genotype–
phenotype correlation. All three patients with congenital
blindness due to Leber’s congenital amaurosis were shown to
have an identical homozygous indel mutation in IQCB1/
NPHP5 (5.5% (CI 0–11.5%) of the total population), suggest-
ing a founder effect. Four patients with Joubert syndrome, RP,
hepatic ﬁbrosis and developmental delay were found to have
TMEM67/MKS3/JBSTS6 mutations (7.3% (CI 0.4–11.5%) of
the total population). These four patients had a similar
appearance to each other, with rectangular faces, square jaws,
and amiable natures despite mental retardation. Another
interesting ﬁnding at this step was that the proportion of
NPHP1 mutations in these patients was relatively lower than
reported.7,8,12 It is not clear whether this difference reﬂects
ethnic characteristics of the study populations or is simply
derived from a selection bias of this study given the small
number of participants. Nonetheless, a majority of the patients
were not given a deﬁnitive diagnosis, similar to that reported in
the literature.7,8,12,38 Those with an atypical phenotype would
have been misclassiﬁed in this step, and their causative genes
would not have been assessed. Therefore, we introduced NGS
technology as our second step.
For better cost-effectiveness, we chose targeted exome
sequencing (TES) instead of whole-genome sequencing or
whole-exome sequencing. TES for disease-related genes with
high read depth enables multiplex screening of candidate
genes.38 In addition to a well-deﬁned set of known NPHP-
RC genes known at the time of study design, we included an
extended set of cilia-related genes in our TES (Supplementary
Table S2), including ARPKD and genes of interest to the
Figure 2 Results of genetic diagnosis for NPHP-RC. One-third (n=19; 34.5%) of the patients with clinical diagnoses of NPHP-RC
obtained a genetic diagnosis by two-step genetic diagnosis using Sanger sequencing (n=12, 21.8%) and targeted exome sequencing
(n=7; 12.7%). Four patients with homozygous total deletion of NPHP1, three with IQCB1/NPHP5, one with CEP290/NPHP6, and four
with TMEM67/MKS3/NPHP11 were detected using Sanger sequencing. Mutations of other genes were detected using targeted exome
sequencing. In addition, heterozygous mutations in NPHP-RC genes were detected in 13 patients (23.6%). NPHP-RC, nephronophthisis-
related ciliopathy.
Genetic diagnosis of Korean NPHP-RC
HG Kang et al
5
Experimental & Molecular Medicine
Ta
bl
e
2
P
ro
ba
bl
y
pa
th
og
en
ic
va
ria
nt
s
in
N
P
H
P-
R
C
pa
tie
nt
s
Pa
tie
nt
ES
R
D
(y
rs
)
Ex
tr
a-
re
na
lm
an
ife
st
at
io
ns
G
en
e
N
uc
le
ot
id
e
ch
an
ge
Am
in
o
ac
id
ch
an
ge
10
00
ge
no
m
es
Ph
yl
o-
P
M
ut
at
io
n
Ta
st
er
Po
ly
-
ph
en
2
SI
FT
FA
TH
M
M
R
ef
.
J-
6
9
.9
N
PH
P1
c.
2
02
9
G
4
C
p.
G
lu
6
7
7
G
ln
-
3
.2
69
D
C
P
D
D
T
J-
1
2
1
.9
IN
VS
/N
PH
P2
c.
7
21
A
4
T
p.
Th
r2
4
1S
er
-
5
.0
55
D
C
P
D
D
T
H
N
F-
3
8
1
6
.7
N
PH
P3
c.
2
85
2
G
4
A
p.
A
rg
9
5
1G
ln
-
4
.5
73
D
C
P
D
T
D
J-
4
6
3
.1
c.
4
24
C
4
T
p.
A
rg
1
4
2*
5
.6
88
D
C
J-
8
3
8
.4
c.
4
24
C
4
T
p.
A
rg
1
4
2*
5
.6
88
D
C
J-
3
5
7
.4
CE
P2
90
/N
PH
P6
c.
5
23
7
G
4
A
p.
A
rg
1
7
46
G
ln
0.
0
0
32
3
.2
8
D
C
P
oD
T
T
J-
7
9
C
K
D
G
LI
S2
/N
PH
P7
c.
5
3G
4
A
p.
A
rg
1
8
G
ln
-
3
.1
83
D
C
P
D
D
T
J-
1
4
0
.6
AH
I1
/J
B
TS
3
c.
3
25
7
A4
G
p.
G
lu
1
0
8
6G
ly
5
0
K
-8
3
.2
O
N
A
,A
D
H
D
,
A
R
B
B
S4
c.
1
54
8
_1
54
9
de
l
p.
5
16
_5
1
7
de
l
5
1
J-
8
4
5
.5
LC
A
,
M
R
,
H
F
c.
1
41
4
A4
G
p.
M
et
4
7
2
Va
l
3
5
K
-9
5
.2
c.
1
41
4
A4
G
p.
M
et
4
7
2
Va
l
3
5
3
5
J-
5
9
1
1
.8
st
ra
bi
sm
us
,
C
VA
,
D
D
,
S
z
M
K
K
S/
B
B
S6
c.
4
16
G
4
A
p.
A
rg
1
3
9G
ln
0.
0
0
18
1
.8
75
D
C
P
D
T
T
K
-1
0
3
R
D
,
H
F
AR
L1
3B
/J
B
TS
8
c.
2
59
A
4
G
p.
Ile
8
7V
al
0.
0
0
18
4
.7
62
D
C
P
D
T
K
-1
1
C
K
D
C
ho
le
do
ch
al
cy
st
,
H
F,
C
ar
ol
i
CC
2D
2A
/J
B
TS
9/
M
K
S6
c.
4
20
2
C4
G
p.
Th
r1
4
01
S
er
0.
0
0
41
5
.8
8
D
C
P
D
T
T
K
-1
2
C
K
D
c.
4
23
8
G
4
A
p.
C
ys
1
41
3
Ty
r
0.
0
0
14
5
.7
25
D
C
P
D
T
T
J-
6
0
1
.2
O
M
A
,
O
N
A
,
C
VA
,
D
D
,
H
F,
ch
ol
e-
do
ch
al
cy
st
TR
IM
32
/B
B
S1
1
c.
4
67
T4
C
p.
Le
u1
5
6P
ro
-
4
.6
35
D
C
P
D
D
T
J-
1
0
2
6
.5
LC
A
,
M
R
,
br
ai
n
at
ro
ph
y,
C
ar
ol
i
di
se
as
e
C5
or
f4
2/
JB
TS
17
c.
8
53
9
G
4
A
p.
A
sp
2
8
4
7
As
n
-
3
.6
08
D
C
P
D
T
T
K
-6
1
2
.0
R
D
PK
H
D
1
c.
9
62
9
C4
G
p.
S
er
3
2
10
C
ys
0.
0
0
37
2
.4
88
D
C
P
D
T
D
A
bb
re
vi
at
io
ns
:
A
R
,
ao
rt
ic
re
gu
rg
ita
tio
n;
A
D
H
D
,
at
te
nt
io
n
de
ﬁ
ci
t
an
d
hy
pe
ra
ct
iv
ity
di
so
rd
er
;
C
VA
,
ce
re
be
lla
r
ve
rm
is
ap
la
si
a;
D
,
da
m
ag
in
g;
D
C
,
di
se
as
e
ca
us
in
g;
D
D
,
de
ve
lo
pm
en
ta
l
de
la
y;
E
S
R
D
,
en
d-
st
ag
e
re
na
l
di
se
as
e;
H
A
,
he
m
ol
yt
ic
an
em
ia
;
H
F,
he
pa
tic
ﬁ
br
os
is
;
M
R
,
m
en
ta
l
re
ta
rd
at
io
n;
N
A
,
no
t
ap
pl
ic
ab
le
;
N
P
H
P
-R
C
,
ne
ph
ro
no
ph
th
is
is
-r
el
at
ed
ci
lio
pa
th
y;
N
T,
no
t
to
le
ra
te
d;
O
M
A
,
oc
ul
om
ot
or
ap
ra
xi
a;
O
N
A
,
op
tic
ne
rv
e
an
om
al
y;
P
D
,
pr
ob
ab
ly
da
m
ag
in
g;
P
oD
,
po
ss
ib
ly
da
m
ag
in
g;
R
D
,
re
tin
al
dy
st
ro
ph
y;
S
N
V,
si
ng
le
-n
uc
le
ot
id
e
va
ria
tio
n;
S
z,
se
iz
ur
e;
T,
to
le
ra
te
d;
yr
s,
ye
ar
s.
Genetic diagnosis of Korean NPHP-RC
HG Kang et al
6
Experimental & Molecular Medicine
authors. Among the variants detected in our second step of
genetic diagnosis, only those that might explain the phenotype
were selected as the most likely pathogenic mutations (n= 13,
Table 2); four known pathogenic mutations, ﬁve frameshift or
truncating mutations and four missense mutations were
predicted to be damaging. The possibility of large deletions
or duplications was also considered, and total deletion of one
NPHP1 allele was detected in one patient (J-39) in whom the
other NPHP1 allele exhibited a heterozygous frame shift
mutation. Other than this case (J-39), no genetic diagnosis
was made involving the ﬁve genes selected for our ﬁrst step.
Given that those with known genetic defects were excluded at
this second step, the efﬁciency of TES could not be assessed.
Overall, this second step of genetic diagnosis mapped genetic
aberrations in known NPHP-RC genes or PKHD1 in 16%
(7 of 43) of the patients. Our results reﬂect a similar mutation-
detection rate to that reported by Halbritter et al.38, where a
molecular diagnosis was obtained in 12% of patients using
high-throughput mutation screening of 13 NPHP genes in a
large population of NPHP-RC patients.
This study has several shortcomings. The number of the
patients is small compared with previous reports,38,39 and
segregation analysis was not available in the majority of the
cases due to the inability to obtain a sample from the parents.
In addition, functional studies of ‘most likely pathogenic’ novel
mutations have not been performed to date. In addition, given
that the coverage of TES of this study was not perfect
(Supplementary Table S3), a second mutation might not be
sequenced, thus warranting Sanger sequencing of the respective
genes with single candidate variants, Unfortunately, further
analysis was not possible in this study because those with single
variants were lost to follow-up. Above all, the set of genes used
for TES reﬂects our knowledge at the time of study design;
therefore, newly discovered genes, such as ZNF423,40
WDR19,41 ANKS6,42 IFT172,43 CEP83 (ref. 44) and DCDC2,45
were not included. On the basis of this study, we are currently
developing our next set of TES by incorporating the recent
discovery of NPHP-RC. Improvements in NSG technology are
expected to increase the rate of genetic diagnosis.
Although the number of patients of this study was not
sufﬁciently large to determine the distribution of genetic
aberration types and loci, this ﬁnding helps to delineate the
characteristics of Korean or Asian NPHP, which enables a
more efﬁcient genetic diagnosis of NPHP-RC in this popula-
tion. On the basis of this study, we are currently assessing the
genetic aberrations of our NPHP-RC patients as follows. Gel
electrophoresis of PCR products of NPHP1 is performed as the
ﬁrst step (step 1), and then one or two particular mutations or
genes are analyzed if the patient has distinctive extra-renal
ﬁndings, such as congenital blindness with c.1523_1524insGA
of IQCB1/NPHP5 or COACH syndrome with a TMEM67/
MKS3/JBSTS6 mutation (step 2). If genetic diagnosis is not
obtained with these ﬁrst two steps, then the TES steps in (step
3) might be replaced by whole-exome sequencing or whole-
genome sequencing in the near future. With expanding
collective knowledge and rapidly evolving technology, both
steps 2 and 3 are expected to simultaneously become more
diverse and more precise, thus yielding a better genetic
diagnosis of NPHP-RC.
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